EUVIMEDEUVIMED entdecken
Crossref

Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab

Philippe Sultanik, Claudia Campani, Edouard Larrey, Bertille Campion, Manon Evain, Charles Roux, Lorraine Blaise, Mathilde Wagner, Marika Rudler, Jean Charles Nault, Dominique Thabut, Manon Allaire

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2024.02.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Philippe Sultanik und 11 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Hypertension, Portal, Bevacizumab. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularHypertension, PortalBevacizumabAntibodies, Monoclonal, HumanizedEsophageal and Gastric VaricesAscitesHumansMaleFemaleMiddle AgedAgedRetrospective StudiesProspective StudiesGastrointestinal HemorrhageSorafenibProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsProportional Hazards Models

Stichwörter der Autor:innen

Acute variceal bleedingAtezolizumab-BevacizumabHepatocellular carcinomaOverall survivalPortal hypertensionPrognostic factors

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabSorafenib

Autor:innen und Institutionen

  • AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France.
  • AP-HP Sorbonne Paris Nord, Hôpitaux Universitaire Paris Seine Saint-Denis, Service d'Hépatologie, Bobigny, France; INSERM UMR 1138, Centre de recherche des Cordeliers, 75006 Paris, France.
  • AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service de radiologie interventionnelle, Paris, France.
  • AP-HP Sorbonne Paris Nord, Hôpitaux Universitaire Paris Seine Saint-Denis, Service d'Hépatologie, Bobigny, France.
  • AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service de radiologie diagnostique, Paris, France.
  • AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France; Sorbonne Université, INSERM, Centre de recherche Saint-Antoine (CRSA), Institute of Cardiometabolism…

Zitieren

APA

Sultanik, P., Campani, C., Larrey, E., Campion, B., Evain, M., Roux, C., Blaise, L., Wagner, M., Rudler, M., Nault, J. C., Thabut, D., & Allaire, M. (2024). Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.02.018

Vancouver

Sultanik P, Campani C, Larrey E, Campion B, Evain M, Roux C, et al. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.02.018

BibTeX
@article{Sultanik2024,
  author = {Sultanik, Philippe and Campani, Claudia and Larrey, Edouard and Campion, Bertille and Evain, Manon and Roux, Charles and Blaise, Lorraine and Wagner, Mathilde and Rudler, Marika and Nault, Jean Charles and Thabut, Dominique and Allaire, Manon},
  title = {Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2024.02.018}
}
Kostenlos starten →